4.4 Article

How Time Rules: Diurnal Motor Patterns in de novo Parkinson's Disease

期刊

JOURNAL OF PARKINSONS DISEASE
卷 11, 期 2, 页码 695-702

出版社

IOS PRESS
DOI: 10.3233/JPD-202352

关键词

Parkinson's disease; circadian rhythm; diurnal rhythm; bradykinesia; motor

资金

  1. Michael J Fox Foundation for Parkinson's Research
  2. AbbVie
  3. Avid
  4. Biogen
  5. Bristol-Myers Squibb
  6. Covance
  7. GE Healthcare
  8. Genentech
  9. GlaxoSmithKline
  10. Lilly
  11. Lundbeck
  12. Merck
  13. Meso Scale Discovery
  14. Pfizer
  15. Piramal
  16. Roche
  17. Servier
  18. Teva
  19. UCB
  20. Britannia Pharmaceuticals

向作者/读者索取更多资源

This study evaluated the impact of clock time on motor performance in de novo drug-naive patients with PD, showing diurnal variations in motor function and bradykinesia scores throughout the day.
Background: Several small-scale studies have shown that motor performance in Parkinson's disease (PD) fluctuates throughout the day. Studies specifically focusing on de novo patients are, however, lacking. Objective: To evaluate the effect of clock time on motor performance in de novo drug-naive patients with PD. Methods: We retrieved MDS-UPDRS III scores for 421 de novo PD patients from the PPMI cohort and stratified them into three groups based on time of assessment: group 1) 7:00-10:00; group 2) 10:00-13:00, and group 3) 13:00-18:00. Groups were compared using Kruskal-Wallis test and results corrected for multiple testing. In addition, we obtained 27 wearable sensor reports, objectively capturing bradykinesia scores in a home setting over a 6-day continuous period, in 12 drug-naive patients from the Parkinson's Kinetigraph Registry held at King's College Hospital London. Time spent in severe bradykinesia scores were broken down into five daytime (06:00-21:00) three-hourly epochs and scores compared using the Friedman test. Results: There were no group differences in demographic or other clinical variables for the cross-sectional analysis. MDSUPDRS III total scores worsened significantly during the course of the day (median 18 (group 1); 20 (group 2); and 23 (group 3); p = 0.001). In the longitudinal wearable sensor cohort, diurnal variations were present in percentage of time spent in severe bradykinesia (p < 0.001) with the lowest percentage during the 09:00-12:00 epoch (69.56 +/- 16.68%), when most patients are awake and start daily activity, and the highest percentage during the 18:00-21:00 epoch (73.58 +/- 16.35%). Conclusion: This exploratory study shows the existence of a diurnal pattern of motor function in patients with de novo PD. The results obtained were corroborated by objective measurements in a small longitudinal cohort confirming a similar diurnal motor score variation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据